A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

ABSTRACT: This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.

DISEASE(S): Carcinoma,Triple Negative Breast Neoplasms,Colorectal Cancer,Fallopian Tube Cancer,Triple Negative Breast Cancer,Neoplasm Malignant,Neoplasms,Carcinoma, Squamous Cell,Squamous Cell Carcinoma Of Head And Neck,Peritoneal Carcinoma,Fallopian Tube Neoplasms,Ovarian Carcinoma,Non-small Cell Lung Cancer,Squamous Cell Carcinoma,Advanced Solid Tumor,Head And Neck Squamous Cell Carcinoma

PROVIDER: 2343359 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR